EHA 2024: Roche's Columvi competes in BiTE battle with positive results in DLBCL [Yahoo! Finance]
Genmab A/S - American Depositary Shares (GMAB)
Company Research
Source: Yahoo! Finance
The trial evaluated Roche's Columvi (glofitamab) in combination with gemcitabine and oxaliplatin (Glofit-GemOx) against GemOx with Roche's MabThera/Rituxan (rituximab) (R-GemOx) for relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) patients in the third plus line setting or transplant-ineligible patients in the second line setting. Even with new targeted therapies and chimeric antigen receptor (CAR)-T cell therapy available, there remains a significant need for additional treatment options in r/r DLBCL, which Columvi aims to meet. Columvi is an intravenously administered bispecific T-cell engager (BiTE), targeting CD3 on T-cells and redirecting them to CD20-expressing cancer B cells, resulting in potent and selective T cell-mediated cytotoxic activity. In the Phase III STARGLO trial, patients in the Glofit-GemOx combination arm received 8 cycles of Columvi + GemOx followed by 4 cycles of Columvi monotherapy with one dose of Roche's Gazyva (obinutuzumab) seven days prio
Show less
Read more
Impact Snapshot
Event Time:
GMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GMAB alerts
High impacting Genmab A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GMAB
News
- Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.MarketBeat
- BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024 [Yahoo! Finance]Yahoo! Finance
- Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical TrialBusiness Wire
- Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.MarketBeat
- Genmab A/S (NASDAQ: GMAB) had its "equal weight" rating re-affirmed by analysts at Morgan Stanley. They now have a $31.00 price target on the stock.MarketBeat